Truist Financial Issues Positive Forecast for Neurocrine Biosciences (NASDAQ:NBIX) Stock Price
by Doug Wharley · The Cerbat GemNeurocrine Biosciences (NASDAQ:NBIX – Get Free Report) had its target price raised by stock analysts at Truist Financial from $140.00 to $155.00 in a research note issued on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Truist Financial’s price objective indicates a potential upside of 4.37% from the company’s current price.
Other equities analysts have also recently issued reports about the stock. Leerink Partners upped their price objective on shares of Neurocrine Biosciences from $160.00 to $170.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 22nd. Piper Sandler boosted their target price on shares of Neurocrine Biosciences from $190.00 to $207.00 and gave the stock an “overweight” rating in a research note on Wednesday. Morgan Stanley upped their price target on shares of Neurocrine Biosciences from $185.00 to $191.00 and gave the stock an “equal weight” rating in a research report on Wednesday. Wedbush raised their price target on shares of Neurocrine Biosciences from $166.00 to $176.00 and gave the company an “outperform” rating in a research note on Wednesday. Finally, Weiss Ratings reiterated a “hold (c+)” rating on shares of Neurocrine Biosciences in a research note on Tuesday, April 21st. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat, Neurocrine Biosciences has an average rating of “Moderate Buy” and an average target price of $183.75.
Read Our Latest Analysis on Neurocrine Biosciences
Neurocrine Biosciences Stock Up 1.0%
Shares of NASDAQ:NBIX traded up $1.50 during trading on Thursday, reaching $148.52. 443,126 shares of the company’s stock traded hands, compared to its average volume of 1,154,948. Neurocrine Biosciences has a fifty-two week low of $115.66 and a fifty-two week high of $160.18. The company has a 50-day simple moving average of $130.75 and a 200-day simple moving average of $137.79. The firm has a market cap of $14.94 billion, a PE ratio of 22.75, a P/E/G ratio of 0.68 and a beta of 0.34.
Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) last issued its quarterly earnings results on Wednesday, February 11th. The company reported $1.88 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.36 by ($0.48). The business had revenue of $805.50 million for the quarter, compared to analysts’ expectations of $804.21 million. Neurocrine Biosciences had a return on equity of 20.49% and a net margin of 21.55%.The business’s revenue for the quarter was up 28.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.69 EPS. On average, equities research analysts forecast that Neurocrine Biosciences will post 6.57 EPS for the current year.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in the stock. JPMorgan Chase & Co. grew its position in shares of Neurocrine Biosciences by 11.0% in the third quarter. JPMorgan Chase & Co. now owns 4,730,152 shares of the company’s stock valued at $664,019,000 after purchasing an additional 468,405 shares in the last quarter. AQR Capital Management LLC boosted its stake in Neurocrine Biosciences by 18.0% during the fourth quarter. AQR Capital Management LLC now owns 3,271,706 shares of the company’s stock worth $462,652,000 after buying an additional 498,058 shares during the last quarter. Geode Capital Management LLC grew its holdings in Neurocrine Biosciences by 1.7% in the 4th quarter. Geode Capital Management LLC now owns 2,059,282 shares of the company’s stock valued at $291,342,000 after buying an additional 34,457 shares in the last quarter. Los Angeles Capital Management LLC grew its holdings in Neurocrine Biosciences by 7.4% in the 4th quarter. Los Angeles Capital Management LLC now owns 1,291,278 shares of the company’s stock valued at $178,248,000 after buying an additional 88,522 shares in the last quarter. Finally, Northern Trust Corp increased its stake in shares of Neurocrine Biosciences by 31.9% in the 4th quarter. Northern Trust Corp now owns 1,221,184 shares of the company’s stock worth $173,201,000 after acquiring an additional 295,470 shares during the last quarter. 92.59% of the stock is currently owned by institutional investors and hedge funds.
Trending Headlines about Neurocrine Biosciences
Here are the key news stories impacting Neurocrine Biosciences this week:
- Positive Sentiment: Q1 results beat expectations — NBIX reported $1.94 EPS and ~$811M in net product sales (up ~44% YoY), reconfirmed full-year INGREZZA guidance and announced strategic moves that management said support 2027 growth. Neurocrine Biosciences Reports First-Quarter 2026 Financial Results
- Positive Sentiment: Analyst bullishness — several firms raised price targets and ratings in quick succession (Piper Sandler, Citigroup, RBC, Wedbush, Guggenheim), signaling increased sell‑side confidence in near- and medium-term growth. Piper Sandler Issues Positive Forecast for Neurocrine Biosciences (NASDAQ:NBIX) Stock Price
- Positive Sentiment: Piper Sandler notably raised its PT to $207 (overweight) and Citigroup lifted its target to $246 (buy), representing large upside from recent levels — these high-profile raises can attract momentum buyers. Neurocrine Biosciences (NASDAQ:NBIX) Price Target Raised to $191.00 at Morgan Stanley
- Positive Sentiment: Peer-reviewed guidance publication for CRENESSITY dosing — new expert recommendations may ease clinician adoption and support label/usage clarity for the CAH indication. Neurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction after Initiating CRENESSITY® (crinecerfont) for the Treatment of Classic Congenital Adrenal Hyperplasia
- Neutral Sentiment: Morgan Stanley raised its price target but kept an “equal weight” stance — the PT move provides some support but the neutral rating tempers a pure buy signal. Neurocrine Biosciences (NASDAQ:NBIX) Price Target Raised to $191.00 at Morgan Stanley
- Neutral Sentiment: Market commentary asking whether recent gains have priced in too much caution suggests some investors are debating valuation after the run-up — watch multiple analysts’ differing targets for evidence of consensus. Is Neurocrine Biosciences (NBIX) Pricing In Too Much Caution After Recent Share Gains?
- Negative Sentiment: Soleno Therapeutics acquisition adds upside but also execution and integration risk — some analysts/commentary frame the deal as “risky upside,” so investors should watch dilution, closing terms and regulatory/timelines. Neurocrine Biosciences: Core Business On Track, Soleno Deal Adds Risky Upside
About Neurocrine Biosciences
Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.
The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.